I would like to say that my experience with Libertas Academica has been excellent. The steps for submitting a manuscript are easy. The review process has been fast and reviewers comments have been kind and very qualified. The communication with the staff is fluent and friendly. I like the regular updates of the progress of my submitted manuscript. I appreciate a lot these advantages.

What is the primary focus of your research?

In this moment and in the past my clinical research has focused primarily on gastrointestinal tumors, mainly colorectal and gastric neoplasms.

I have been working in several projects related with new clinical and pathological prognostic/predictive factors, tumoral markers and its clinical utility in different clinical scenarios and biomarkers.

My work has also explored the relationship between costs and effectiveness of various strategies for monitoring colon cancer.

What are the most exciting developments arising from current research in your area?

The discovery of new biomarkers in gastrointestinal tumors.

Who are your main collaborators? Please describe your work with them.

I had the good fortune to work with experts from many different fields, including pathologists, radiotherapists, surgeons, biochemical colleagues, gastroenterologists, radiologists, pharmacists. They all have been very motivated by this research.

Currently the teams are multidisciplinary because this is the only way to achieve the best care for the patients and the most competent research.

How did you come to be working in your research area?

I am a young Medical Oncologist with a great interest in improving quality of care in gastrointestinal tumors.

I realize that as a first step to achieve the best quality of care in current clinical practice is the motivation of all specialists involved in cancer care and close collaboration within multidisciplinary teams.

But I am also aware of the limitations of the current treatment for these diseases. This motivated me to train in molecular oncology with the aim of carrying out translational projects with the hope of contributing to the improvement of patient's survival and quality of life.

What do you think about the development of open access publishing?

I really appreciate open access publishing because this facilitates the access to quality investigations to all researchers around the world.

What articles and/or books have you published recently?

• Uña E. "Atypical presentation of acute neurotoxicity secondary to oxaliplatin". J Oncol Pharm Pract. 2009 Dec 16.
• Uña E, Trueba J, Montes JM."Unexplained liver laceration after metastasis radiofrequency ablation". World J Gastroenterol. 2009 Oct 28;15(40):5103-5.
• Uña E."Gastric cancer: predictors of recurrence when lymph-node dissection is inadequate". World J Surg Oncol. 2009 Sep 17;7:69.
• Uña E. "A Different Variable to Stratify Risk in Resected Gastric Cancer".
• Ann Surg Oncol. 2009 Oct 31.
• Uña E. "Sexual problems after breast cancer: the underreported symptoms".
• Gynecol Oncol. 2010 Jan;116(1):147. Epub 2009 Oct 27.
• Uña E. "A Commentary on “Risk Factors for Renal Cell Cancer in a Japanese Population”. Clinical Medicine: Oncology 2009:3;87-90.
• Uña E, Jiménez M. "Gastric Adenocarcinoma: Is Computed Tomography (CT) Useful in Preoperative Staging?". Clinical Medicine: Oncology 2009:3;91-97.
• Uña E, Cuadrillero F, López-Lara F. "Drug extravasation: a dreaded complication". BMJ Case Reports 2009 [doi:10.1136/bcr.09.2008.0887]
• Uña E, Tejeiro M, Alvarez M. "Primary Peritoneal Malignant Mixed Müllerian Tumor in a Young Woman: Achieving the Best Clinical Benefit". Case Rep Oncol 2009;2:162-167 (DOI: 10.1159/000235912)
• Uña E. Clinical benefit and safety in gastric cancer´s treatment. Gastric Cancer Journal (Spanish edition)2009;3:20-25.
• Uña E, Gandía F, Duque JL. "Tongue paralysis after orotracheal intubation in a patient with primary mediastinal tumor". Cases Journal 2009, 2:9301doi:10.1186/1757-1626-2-9301.
• Losa R, Fra J, López-Pousa A, Sierra M, Goitia A, Uña E, Nadal R, Del Muro JG, Gión M, Maurel J, Escudero P, Esteban E, Buesa JM. "Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas". Cancer Chemother Pharmacol. 2007 Feb;59(2):251-9.
• Esteban E, Fra J, Fernández Y, Corral N, Vieitez JM, Palacio I, de Sande JL, Fernández JL, Muñiz I, Villanueva N, Estrada E, Mareque B, Uña E, Buesa JM, Lacave AJ; Grupo Oncológico del Norte de España (GON). "Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: results of a prospective randomized phase II study". Invest New Drugs. 2006 May;24(3):241-8.